Avalo Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Revenue	0.44	1.92	18.05	5.4	6.7	Upgrade
Revenue Growth (YoY)	-77.08%	-89.34%	234.40%	-19.42%	-0.76%	Upgrade
Cost of Revenue	15.28	9.95	25.99	50.12	25.24	Upgrade
Gross Profit	-14.84	-8.02	-7.94	-44.72	-18.54	Upgrade
Selling, General & Admin	17.24	10.3	13.91	24.66	19.76	Upgrade
Research & Development	8.8	5.12	8.05	11.21	7.26	Upgrade
Operating Expenses	26.04	15.42	22	37.41	28.76	Upgrade
Operating Income	-40.87	-23.44	-29.94	-82.13	-47.29	Upgrade
Interest Expense	-	-3.42	-4.17	-2.39	-	Upgrade
Interest & Investment Income	3.32	-	-	-	0.05	Upgrade
Other Non Operating Income (Expenses)	30.18	-0.76	-0.02	-0.02	0.41	Upgrade
EBT Excluding Unusual Items	-7.37	-27.62	-34.13	-84.55	-46.84	Upgrade
Merger & Restructuring Charges	-	-	-7.5	-	-	Upgrade
Impairment of Goodwill	-	-3.91	-	-	-	Upgrade
Gain (Loss) on Sale of Investments	-	-	-	-	5.21	Upgrade
Pretax Income	-35.02	-31.53	-41.63	-84.55	-67.18	Upgrade
Income Tax Expense	0.11	0.01	0.03	-0.2	-2.79	Upgrade
Earnings From Continuing Operations	-35.13	-31.54	-41.66	-84.35	-64.38	Upgrade
Earnings From Discontinued Operations	-	-	-	-0.03	0.88	Upgrade
Net Income	-35.13	-31.54	-41.66	-84.38	-63.5	Upgrade
Net Income to Common	-35.13	-31.54	-41.66	-84.38	-63.5	Upgrade
Shares Outstanding (Basic)	4	0	0	0	0	Upgrade
Shares Outstanding (Diluted)	7	0	0	0	0	Upgrade
Shares Change (YoY)	2599.19%	608.45%	8.32%	41.86%	28.52%	Upgrade
EPS (Basic)	-7.94	-113.58	-1062.65	-2331.41	-2489.12	Upgrade
EPS (Diluted)	-20.91	-113.58	-1062.65	-2331.41	-2489.12	Upgrade
Free Cash Flow	-49.06	-30.84	-26.85	-71.01	-40.6	Upgrade
Free Cash Flow Per Share	-6.54	-111.04	-684.81	-1961.95	-1591.55	Upgrade
Gross Margin	-	-	-43.98%	-	-276.70%	Upgrade
Operating Margin	-9267.80%	-1218.50%	-165.86%	-1521.56%	-705.99%	Upgrade
Profit Margin	-7965.76%	-1639.50%	-230.78%	-1563.10%	-947.90%	Upgrade
Free Cash Flow Margin	-11123.81%	-1602.81%	-148.72%	-1315.39%	-606.09%	Upgrade
EBITDA	-40.7	-23.29	-29.77	-80.48	-45.45	Upgrade
EBITDA Margin	-	-	-164.94%	-	-	Upgrade
D&A For EBITDA	0.17	0.16	0.17	1.66	1.84	Upgrade
EBIT	-40.87	-23.44	-29.94	-82.13	-47.29	Upgrade
EBIT Margin	-	-	-165.86%	-	-	Upgrade
Revenue as Reported	0.44	1.92	18.05	5.4	6.7	Upgrade

Updated Mar 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q